<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396071</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2387</org_study_id>
    <nct_id>NCT00396071</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin</brief_title>
  <official_title>A Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Effect of Vildagliptin on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This mechanistic study will evaluate the effect of vildagliptin on glucose-stimulated insulin&#xD;
      secretion to improve the incretin effect in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-peptide IAUC (0-4hr)</measure>
    <time_frame>2 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin secretion rate (ISR) relative to glucose (0-2hr)</measure>
    <time_frame>after 2 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial C-peptide</measure>
    <time_frame>after two weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulin</measure>
    <time_frame>after two weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucagon</measure>
    <time_frame>after two weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial GLP-1</measure>
    <time_frame>after 2 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 100 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <description>vildagliptin 100 mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes on metformin for at least 3 months and have been on a&#xD;
             stable dose of at least 1500 mg daily for a minimum of 4 weeks&#xD;
&#xD;
          -  Agreement to maintain the same dose of metformin throughout the study&#xD;
&#xD;
          -  Body mass index (BMI) in the range of 22-35 kg/m2&#xD;
&#xD;
          -  HbA1c in the range of 7.0 to 9.0%&#xD;
&#xD;
          -  FPG &lt;200 mg/dl (11.1 mmol/L)&#xD;
&#xD;
          -  Agreement to maintain prior diet and exercise habits during the full course of the&#xD;
             study&#xD;
&#xD;
          -  Ability to comply with all study requirements and signed informed consent to&#xD;
             participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of type 1 diabetes&#xD;
&#xD;
          -  A history of acute metabolic diabetic complications&#xD;
&#xD;
          -  Evidence of significant diabetic complications&#xD;
&#xD;
          -  Insulin treatment for longer than 10 days within the past 6 months&#xD;
&#xD;
          -  Treatment with any oral anti-diabetic other than metformin within 3 months prior to&#xD;
             visit 1&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Zentrum Bad Lauterberg</name>
      <address>
        <city>Bad Lauterberg</city>
        <zip>37431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Vardarli I, Nauck MA, KÃ¶the LD, Deacon CF, Holst JJ, Schweizer A, Foley JE. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as &quot;isoglycemic&quot; intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 Apr;96(4):945-54. doi: 10.1210/jc.2010-2178. Epub 2011 Jan 14.</citation>
    <PMID>21239518</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>vildagliptin</keyword>
  <keyword>incretin effect</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

